Protagonist (PTGX) | Stock Overview & Key Data
Protagonist Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $106.90 on April 17, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Protagonist
PTGX
|
6.76B Mid-cap | -6.65% | -4.13% | 4.50% | 10.85% | 9.44% | 109.73% | 253.05% | 186.01% | 760.50% | 760.50% | 760.50% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Arrowhead
ARWR
|
10.42B Large-cap | -8.15% | -5.03% | 13.18% | 11.50% | 7.02% | 384.82% | 116.12% | 2.32% | 1,173.04% | 1,291.25% | 50.41% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | -0.45% | 4.37% | 42.32% | 57.95% | 30.66% | 122.97% | 216.35% | 282.39% | 2,961.10% | 2,485.23% | 2,485.23% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | -21.90% | -17.38% | -12.35% | 49.84% | -2.61% | 807.83% | 2,210.03% | 21.08% | -16.07% | -16.07% | -16.07% |
Ownership & Short Interest
Calculate Your Protagonist Investment Returns
Long-Term Investment Performance Analysis
Protagonist stock price in Aug 2016 was $11.57, A $1,000.00 lump sum investment in Protagonist made 9 years ago would be worth approximately $8,246.33 today, representing a exceptional return of 724.63%. This translates to an annualized return (CAGR) of 23.97%.
9 Years 9 Months Investment Scenario (Aug 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is PTGX's 52-week high and low?
- In the last 52 weeks, Protagonist reached a high of $107.84 (on April 1, 2026) and a low of $49.38 (on July 8, 2025).
- What is the market cap and P/E ratio for PTGX?
- Curious about Protagonist's size and valuation? Its market capitalization stands at 6.76B. When it comes to valuation, the P/E ratio (trailing twelve months) is 139.52, and the forward P/E (looking ahead) is -244.06.
- Does PTGX pay dividends? If so, what's the yield?
- As for dividends, Protagonist isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Protagonist's main competitors or similar companies to consider before investing?
When looking at Protagonist, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Arrowhead
ARWR10.42B Healthcare Biotechnology 384.82% 116.12% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 122.97% 216.35% Praxis Precision
PRAX9.60B Healthcare Biotechnology 807.83% 2,210.03% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Protagonist Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Protagonist's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -20.18%, the Debt to Equity ratio from the most recent quarter is 1.68, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for PTGX?
- Looking at Protagonist's growth, its revenue over the trailing twelve months (TTM) was $46M. Compared to the same quarter last year (YoY), quarterly revenue grew by -95.60%, and quarterly earnings saw a YoY growth of -95.64%.
- How much of PTGX stock is held by insiders and institutions?
- Wondering who owns Protagonist stock? Company insiders (like executives and directors) hold about 1.23% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 113.64%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.